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Abstract
Background: Children born small for gestational age (SGA) experience higher rates of morbidity and mortality
than those born appropriate for gestational age. In Latin America, identification and optimal management of
children born SGA is a critical issue. Leading experts in pediatric endocrinology throughout Latin America
established working groups in order to discuss key challenges regarding the evaluation and management of
children born SGA and ultimately develop a consensus statement.
Discussion: SGA is defined as a birth weight and/or birth length greater than 2 standard deviations (SD) below
the population reference mean for gestational age. SGA refers to body size and implies length-weight reference
data in a geographical population whose ethnicity is known and specific to this group. Ideally, each country/region
within Latin America should establish its own standards and make relevant updates. SGA children should be
evaluated with standardized measures by trained personnel every 3 months during year 1 and every 6 months
during year 2. Those without catch-up growth within the first 6 months of life need further evaluation, as do
children whose weight is ≤ -2 SD at age 2 years. Growth hormone treatment can begin in SGA children > 2 years
with short stature (< -2.0 SD) and a growth velocity < 25th percentile for their age, and should continue until final
height (a growth velocity below 2 cm/year or a bone age of > 14 years for girls and > 16 years for boys) is
reached. Blood glucose, thyroid function, HbA1c, and insulin-like growth factor-1 (IGF-1) should be monitored once
a year. Monitoring insulin changes from baseline and surrogates of insulin sensitivity is essential. Reduced fetal
growth followed by excessive postnatal catch-up in height, and particularly in weight, should be closely monitored.
In both sexes, gonadal function should be monitored especially during puberty.
Summary: Children born SGA should be carefully followed by a multidisciplinary group that includes
perinatologists, pediatricians, nutritionists, and pediatric endocrinologists since 10% to 15% will continue to have
weight and height deficiency through development and may benefit from growth hormone treatment. Standards/
guidelines should be developed on a country/region basis throughout Latin America.
Background
Low birth weight (< 2500 g) is prevalent in many coun-
tries and poses a significant public health problem con-
tributing to a variety of short- and long-term negative
effects. While about half of low-birth-weight infants in
the industrialized world are born preterm (< 37 weeks’
gestation), most of these infants are born full term in
the rest of the world [1]. The United Nations Children’s
Fund State of the World’s Children Report, 2003 [1,2],
noted a 14% overall world prevalence of low birth
weight, with the highest prevalence of low birth weight
in South Asia (26%), with rates of 14% in developing
countries, 9% in Latin America and the Caribbean
(Table 1). About two-thirds of births in parts of Asia,
Africa, and Latin America go unreported because many
deliveries occur in small clinics or private homes [1],
hence, it is logical to assume that the number of low-
weight births is also underreported.
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likely in children of low birth weight or born small for
gestational age (SGA) than children born appropriate
for gestational age (AGA) [3-5]. Hence, it is imperative
to begin managing the health care of these children as
early as possible to achieve optimal outcomes.
The development of the 2007 consensus statement on
the management of children born SGA by the Interna-
tional Societies of Pediatric Endocrinology and the
Growth Hormone Research Society [3] prompted lead-
ing experts to develop a similar consensus statement for
Latin America. They held the first meeting in Lima,
Peru, in October 2008, where three working groups dis-
cussed key issues to address within the consensus, speci-
fically regarding the evaluation and management of
children born SGA within Latin America. In March,
2009, the group met in Prague, Czech Republic, to
further discuss and agree on the elements of a consen-
sus document. Shortly thereafter, a consensus report
was produced, which is presented here in final form.
This paper presents a summary of the key issues dis-
cussed at the conferences regarding the clinical identifi-
cation and optimal management of children born SGA.
Discussion
Definition of SGA
The definition of SGA is unclear. The World Health
Organization (WHO) defines children born SGA or
after intrauterine growth retardation (IUGR) as those
with birth weight below the 10th percentile of the
recommended gender-specific birth weight for refer-
enced gestational age. Where gestational age is not
available, the birth weight of < 2500 g should be consid-
ered low birth weight [6]. This definition is also used in
obstetrics and neonatal guidelines due to the fact that
these children represent groups with the highest neona-
tal morbidity and mortality [6-9]. However, neonates
with either low birth weight or length–or both–for
gestational age should be considered SGA.
For the purpose of this consensus, an SGA child is a
child whose birth weight and/or birth length is at least 2
standard deviations (SD) below the mean for its gesta-
tional age [10].
Notably, we recommend that the term SGA not be
used as a synonym for IUGR. The term IUGR refers to
insufficient growth of the fetus and should only be used
if at least 2 assessments of intrauterine growth are avail-
able and the fetus is not growing appropriately. SGA
refers to body size–a low weight and/or length for a
known gestational age–and is preferred in the absence
of information about fetal growth.
Epidemiology
Although many countries lack data on the actual inci-
dence of children born SGA, there have been estimates
ranging from 2.3% (< -2 SD) to 10% (< 10th percentile),
depending on the definition used [11]. In Latin America,
an evaluation between 1999 and 2004 at the Hospital
Militar Central in Bogotá, Colombia, showed that 3.6%
of 14,274 newborns were born SGA, defined as < 10th
percentile weight and length (personal communication,
Dr Teresa Ortiz). In Mexico, a review of 31,209 children
born between 2000 and 2002 reported a 6% prevalence
of SGA (≤ -2 SD weight) in the general population, ran-
ging from 6.5% to 7.2% among salaried workers from
Mexico City (n = 807) and from 3.7% to 6.9% in non-
salaried farmers from small rural communities (n = 339)
[12]. The discrepancy in SGA births among Latin Amer-
ican countries may also depend on which growth chart
is being used, if it has been appropriately updated, and
if it reflects the ethnicity mixture within a given country.
In addition, the number of SGA births may also be
impacted by the wide range of socioeconomic status and
percentages of malnutrition that exist within Latin
American countries.
Initial identification
Considering the high morbidity and mortality rates in
this population, prompt identification is critical. SGA
newborns are 5 times more likely to die in the neonatal
period and 4.7 times more likely to die in their first year
of life [13]. Prematurity and low birth weight are signifi-
cant causes of death in low- and middle-income coun-
tries [13,14]. SGA newborns are at a higher risk of
developing hypertension and type 2 diabetes as adults
[13,15,16]. They are also at higher risk of low IQ and
presenting with short stature [13,15,16]. Children with
low birth weight and subsequent early postnatal catch-
up growth are at increased risk for obesity in childhood
Table 1 Prevalence of low birth weight worldwide by
region
Regions % of infants with low birth
weight 1995-2000
South Asia 26
Sub-Saharan Africa 12
Middle East & North Africa 11
Latin America & Caribbean 9
CEE/CIS and Baltic States 9
Least developed countries 18
World 14
Developing countries 14
Industrialized countries 7
Abbreviations: CEE, Central and Eastern Europe; CIS, Commonwealth of
Independent States.
Source: United Nations Children’s Fund 2003 State of the world’s children
report, 2003. New York: UNICEF, 2003. (2) Available at: http://www.unicef.org/
sowc03/contents/index.html. Accessed September 8, 2010.
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stroke, and diabetes mellitus–all of which are among
WHO’s top 10 causes of death worldwide
[12,13,15,17,18].
Accurate determination of gestational age is essential
for a diagnosis of SGA. The menstrual history of the
mother and the use of ultrasound, usually in week 16 of
gestation, increase the accuracy of the estimation. When
this information is not available, physical examination of
the newborn can be helpful (Ballard score [19]). Mea-
surements of birth weight, length, and head circumfer-
ence should be performed by trained personnel and
follow appropriate, standardized procedures. The accu-
racy of newborn body measurements is paramount.
Electronic scales for measuring weight and paper tapes
for measuring head circumference are considered reli-
able methods [20-22]. Head circumference should be
assessed at birth, as well as at first pediatric analysis
during the first month of life in order to derive a more
consistent measurement. Measurement of an infant’s
length can be less reliable [20,23], but its accuracy may
be improved if the infant is measured by 2 people using
a headboard [20,24]. The values should be compared
with population-specific reference tables, allowing for
classification as AGA or SGA, according to the chosen
definition [25]. Country-specific reference charts for size
at birth are preferred [26], but in some Latin American
countries, these specific reference charts for size at birth
are still unavailable. There is a critical need to develop
reference charts for size at birth in each country, other-
wise the definition of SGA could still be misleading in
certain areas.
Growth references specific to Argentina have been
used for more than 2 decades [27,28]. In 2009, Lejar-
raga et al published refinements to these charts by
recalculating percentiles and lambda-mu-sigma (LMS)
values from birth to maturity and incorporating
updated WHO data from birth to age 2 years [29].
The Argentine growth charts are available at: http://
www.garrahan.gov.ar/tdecrecimiento. When a national
reference for preterm growth and size at birth is not
available, the Babson and Benda growth charts updated
in 2003 are recommended [20,30]. Children born pre-
maturely (< 37 weeks gestational age) should be evalu-
ated considering their special characteristics. Among
them will be newborns SGA and AGA and appropriate
references for preterm must be used [20]. However, it
is important to recognize that defining SGA in preterm
infants may be difficult since preterm reference charts
do not typically include extremely preterm infants.
Every country should make an effort to collect growth
charts that represent a large number of premature
infants of different gestational ages for more informed
datasets.
Causes of SGA
Many risk factors associated with low birth weight sig-
nificantly overlap with risk factors associated with pre-
maturely born infants. The characterization of an SGA
infant should take into account the mother’sh e i g h t ,
weight, parity, age, ethnicity, and geographic location.
Maternal malnutrition (ie, an insufficient weight increase
during gestation), placental size and dysfunction, and
the presence of maternal diseases should also be estab-
lished [11]. Smoking, alcohol consumption, and drug
use are preventable causes of IUGR; therefore, the
mother’s habits relative to these factors should be
recorded. Fetal growth depends both on genetic factors
and an optimal maternal-fetal health environment that
allows the free flow of nutrients and oxygen, in addition
to the integrity of growth factors IGF-1, IGF-2, and
insulin synthesis and action. In addition, an excess of
cortisol in fetal circulation produces a derangement in
fetal growth.
Growth and SGA
Follow-up
Most children born SGA recover from their weight and
height deficiency. Term SGA newborns generally com-
plete catch-up growth at about 2 years of age [31-33],
whereas premature newborns may take longer to catch
up than full-term newborns [34]. The recovery is com-
pleted when they reach their genetic potential as deter-
mined by parental height [33]. However, 10% to 15% of
those born SGA will continue to have significantly short
stature (height ≤-2 SD) during childhood and adult life
[31,35,36].
Approximately 90% of healthy, full-term children born
SGA will undergo catch-up growth during their first 2
years of life [31], which can occur as early as 12 weeks
postnatal age [37]. As such, this consensus recommends
that children born SGA should be evaluated every 3
months during the first year of life and every 6 months
during the second year. Weight, length, and head cir-
cumference should be measured at all appointments. A
child who does not show catch-up growth during the
first 6 months of life should be evaluated further. The
same recommendation is valid for a child whose weight
is ≤ -2 SD at age 2 years. In these cases, common pedia-
tric diseases, genetic disorders and hypothalamic and/or
pituitary dysfunctions should be ruled out. SGA children
who do not recover height generally have an adequate
endogenous growth hormone (GH) secretion in
response to pharmacological tests. However, they often
have low serum IGF-1 levels and altered physiological
GH secretion patterns [32,38].
Ideally, SGA implies length and weight reference data
in a geographical population whose ethnicity is known.
If local charts endorsed by local Pediatrics Associations
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growth charts could be used (http://www.who.int/child-
growth) [39]. The WHO charts combine data of a longi-
tudinal follow-up from birth to 24 months and a cross-
sectional survey of children aged 18 to 71 months;
breastfed infants and young children from Brazil,
Ghana, India, Norway, Oman, and USA were included.
After age 5 years, the WHO Reference 2007–an update
of the 1977 National Center for Health Statistics
(NCHS)/WHO reference, using the original NCHS data
set supplemented with data from the WHO child
growth standards–is recommended http://www.who.int/
growthref/en/[40].
Criteria for initiation of growth hormone treatment
Age
GH treatment (somatropin [rDNA origin] for injection)
was approved by the US Food and Drug Administration
(FDA) in July 2001 for the long-term treatment of
growth failure in children born SGA who did not have
sufficient catch-up growth by age 2 years [10,41,42].
That is, children older than 2 years of age with either
short stature (< -2 SD) and a birth weight < 2500 g at a
gestational age ≥37 weeks [41], with birth weight or
length < 3rd percentile for gestational age [41], or with
ponderal weight index (100 × [weight in g] ÷ [length in
cm]
3) < -2 SD.
In Europe, GH treatment was approved by the Com-
mittee for Proprietary Medicinal Products (CPMP) in
June 2003 for children born SGA (birth weight and
length < -2 SD) with short stature (height < -2.5 stan-
dard deviation score [SDS] and parental adjusted height
<- 1 . 0S D S )a n dw h of a i lt os h o wc a t c h - u pg r o w t hb y
age 4 years or older [43].
Argente and colleagues recently analyzed the outcome
of very young SGA children, between ages 2-5 years,
treated with GH [44]. They reported a greater increase
in height velocity in the group younger than 4 years of
age. Considering this finding, starting treatment shortly
after age 2 years should be considered, particularly
when growth velocity is below the 25th percentile for
the child’s age.
GH dosing recommendations
A clear dose-dependent increase in height velocity has
b e e no b s e r v e di nc h i l d r e nb o r nS G Ad u r i n gt h ef i r s t
years of treatment [10,45]. Optimal height is obtained
with longer GH treatment before the start of puberty
[46]. Furthermore, the height gain obtained with treat-
ment during the prepubertal years is maintained until
final height [46]. GH dosing recommendations for chil-
dren born SGA differ in the US and Europe–the recom-
mended dosage in the US is up to 0.48 mg/kg per week
(68.5 μg/kg/day) divided into daily doses [41] and the
corresponding dosage in Europe is 0.035 mg/kg/day
continued until full height is reached [43]. We recom-
mend an initial GH dose of 0.33 mg/kg/week (≈ 47 μg/
kg/day or 0.15 IU/kg/day), with dose adjustments based
on weight gain for those children with stature < -2 and
> -3 SD. However, for those children with height < -3
SD, when rapid catch-up growth is desired, a higher
dose might be indicated (0.48 mg/kg/week) without
dose adjustment based on weight until they reach the
regular dose of 0.33 mg/kg/week and IGF-1 levels within
upper normal range. With this schedule a higher dose
from the beginning of therapy will induce faster catch-
up growth in those children who are more severely
compromised.
Baseline assessment and follow-up during GH treatment
Baseline studies including hormonal (thyroid, IGF-1)
and metabolic measurements (glucose, insulin, and lipid
profile) are mandatory before initiation of GH treat-
ment. Careful follow-up during GH treatment is recom-
mended. The child should be evaluated every 3 to 6
months (physical examination and laboratory evaluation)
by a physician experienced using GH to determine if
dose adjustment is necessary [47]. Blood glucose, thyr-
oid function, HbA1c, and IGF-1 should be monitored
once a year except in cases exhibiting clear clinical evi-
dence of insulin resistance or an HbA1C of 6% at the
beginning of treatment. While it is necessary to measure
IGF-1 levels once a year, twice a year is preferred. Mon-
itoring changes from baseline insulin levels and surro-
gates of insulin sensitivity are also helpful in the follow-
up of these children [48]. Notably, GH-associated
adverse events are not more common in SGA than
other conditions treated with GH [3]. Patients with a
strong familial history of type 2 diabetes could be evalu-
ated with the use of an oral glucose tolerance test
(OGTT) at baseline and then as appropriate, contingent
on 3- and 6-month laboratory values.
Criteria to stop GH treatment
Treatment with GH should continue if a positive growth
response is observed within the first year of treatment
(height velocity > +0.5 SDS) [3]. Treatment in adoles-
cence should be stopped if the height velocity is below 2
cm/year and bone age is > 14 years for girls and > 16
years for boys, corresponding to closure of the epiphy-
seal growth plates [43].
Adverse events
Continuous GH therapy is not associated with serious
adverse events in short children who are born SGA
[49-51]. However, because of increased prevalence of
metabolic disturbances and high blood pressure in
adults born SGA [15,17,18,52-55], specific attention
must be paid to glucose homeostasis and weight gain in
short SGA children treated with GH. Previous studies
have demonstrated that discontinuation of long-term
GH treatment in SGA adolescents normalized insulin
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increase during GH therapy [56,57].
GH treatment does not appear to be associated with
an increased risk of malignancy [57]. It is recommended
that IGF-1 concentrations should be monitored and GH
dose should be reduced in children with a plasma IGF-1
above +2 SD [58,59]. In a long-term follow-up study of
GH therapy in short children born SGA, increased IGF-
1 levels were completely reversed after discontinuing
GH [60].
Puberty and SGA
Pubertal growth
Current data with regard to initiation, tempo, duration,
and progression of puberty in children born SGA are
limited and difficult to compare due to the differences
in methodologies in the available literature (eg, SGA
with or without catch-up, differences in the definition of
SGA). Some studies show a normal but earlier pubertal
development; however, others report a late pubertal
start [61-63].
In human models, decreased pubertal growth has been
observed [64]. In female models, a delayed growth of
approximately 4 cm has been reported [65]. This finding
suggests that there are gender-dimorphic susceptibilities
for SGA postnatal pubertal changes [62,65]
With regard to the age of pubertal initiation, most
studies report an age similar to that for children born
AGA [62]; however, several researchers have shown
either an earlier pubertal timing [61,65-67], or late
tempo [68,69]. In an animal study analysis, investigators
postulated that a higher level of exposure to insulin in
postnatal life in those born SGA with accelerated weight
gain may induce an earlier, exaggerated secretion of LH
that leads to earlier pubertal timing [70].
Menarcheal age has also been reported as being earlier
or within normal range [62,64,66,71-75]. Girls born SGA
who had rapid weight gain in first months of infancy are
more likely to have premature adrenarche. These girls
can have earlier puberty and menarche than AGA girls
with premature adrenarche [73,76].
Although bone age assessment is used to evaluate ske-
letal maturity, it has been suggested that use of bone
age for final height prognosis is of limited value in chil-
dren born SGA and thus should be used with caution
[77].
SGA children without catch-up growth who are trea-
ted with GH have a normal pubertal timing and pro-
gression [68]. However, the use of GH near the
beginning or late in puberty has not been shown to
improve final height significantly [57,59].
Female gonadal function
Girls born SGA with catch-up growth present with
lower insulin sensitivity, and there are data showing an
increased incidence of adrenal and ovarian hyperandro-
genism clinically evident as precocious pubarche
[76,78,79]. However, these data were collected in a
selected population from an endocrine clinic [76,78,79]
and other studies have not confirmed these associations
[80-84]. Thus far, there are insufficient data to confirm
an altered ovarian function, fertility, or earlier meno-
pause in these girls.
Metformin use
There is a preliminary report which suggests that the
early use of metformin at a perimenarcheal age in low-
birth-weight girls with a history of precocious pubarche
prevents progression to polycystic ovary syndrome
(PCOS); improves insulin sensitivity; and normalizes
body composition, lipid profiles and GH secretion [85].
I nas u b s e q u e n tr e p o r ti nl o w - b i r t h - w e i g h tg i r l sw i t h
precocious pubarche by the same group, metformin
treatment was associated with a less-adipose body com-
position; a 0.4-year delay in the clinical onset of puberty;
a delay of at least 1 year in puberty-associated increase
in circulating IGF-I; and a maintenance of height gain
[86]. These findings remain to be confirmed by other
studies and thus are still considered preliminary.
Male gonadal function
Little is known about the long-term effects of IUGR or
being born SGA and their relationship to hypothalamic-
pituitary-gonadal function in males [87]. Low birth
weight has been associated with an increased frequency
of hypospadia, cryptorchidism, and testicular cancer
[87]. This cluster is known as testicular dysgenesis syn-
drome and a common fetal origin has been proposed
for this association [87-91]. There are insufficient data
about seminal quality and the relationship with catch-up
growth or GH treatment in these individuals. On the
other hand, some differences in the levels of pituitary
and testicular hormones and in testicular volumes have
been reported [92]. However, there is no consensus in
this regard and no separation with individuals who had
cryptorchidism [93]. Further studies to evaluate the
impact of IUGR and SGA on the hypothalamic-pitui-
tary-testicular axis are warranted.
SGA and Metabolic Risks
A significantly increased risk of developing cardiovascu-
lar disease (hypertension and dyslipidemia) and type 2
diabetes during adulthood has been associated with low
birth weight [52-54,94]. Three main hypotheses have
been proposed to explain the association between low
birth weight and increased metabolic risks. The fetal
cortisol hypothesis postulated that maternal nutrient
restriction may act to reprogram the development of the
pituitary-adrenal axis, resulting in excess glucocorticoid
exposure and adverse health outcomes in later life. In
this hypothesis, placental 11 beta-hydroxysteroid
Boguszewski et al. BMC Pediatrics 2011, 11:66
http://www.biomedcentral.com/1471-2431/11/66
Page 5 of 10dehydrogenase (11 beta-HSD) plays a key role by con-
verting active cortisol to inactive cortisone. This enzyme
guards the fetus from the growth-retarding effects of
maternal glucocorticoids [95-97].
The second alternative hypothesis is the fetal insulin
hypothesis which proposes that genetically determined
insulin resistance results in impaired insulin-mediated
growth in the fetus, as well as insulin resistance in adult
life [98]. There is evidence to support this hypothesis in
a minority of low-birth-weight cases. For example,
monogenic diseases with impaired sensing of glucose,
lowered insulin secretion or increased insulin resistance
are associated with impaired fetal growth.
The most plausible explanation of this association,
however, is the catch-up growth hypothesis. Children
born SGA may present with a decreased insulin sensi-
tivity early in life [15,99-101]. In the first study to eval-
uate insulin secretion and sensitivity in both SGA and
AGA children from birth to age 1 year [99], investiga-
tors from the University of Chile, Santiago, reported
that by age 1 year, the SGA children with catch-up
weight gain (ie, weight gain SD score > 0.67) had
higher fasting insulin levels and insulin resistance
(insulin area under the curve during IV glucose) than
AGA children. In a follow-up study of these subjects,
the investigators reported that gains in weight SD
scores continued to age 3 years in the children born
SGA, and insulin resistance also progressed during this
period [15]. At age 3 years, no differences in weight or
BMI were seen between these SGA and AGA children,
nor were there differences between the groups in first-
phase insulin secretion. However, SGA children had a
lower glucose disposition index (lower beta cell com-
pensation) that persisted after postnatal weight gain.
The SGA children also exhibited marked transition
from lower pre-fed insulin and increased insulin sensi-
tivity at birth to insulin resistance by age 3 years. The
investigators noted this transition was related to rapid
postnatal catch-up weight gain [15], which may be
related to an increased tendency toward central fat
deposition. They recommended long-term monitoring
of glucose homeostasis in all SGA children regardless
of postnatal catch-up growth. Thus, children born
SGA should not be allowed to gain weight too rapidly
or excessively in an effort circumvent the development
of metabolic disturbances.
The pathophysiological mechanisms of insulin resis-
tance are possibly secondary to a relative prolonged
nutritional deficiency in the fetus, during which time
the fetal metabolism constantly readjusts to slow growth
with relative resistance to insulin, IGF-1, and GH. When
this “adaptation” is inconsistent with postnatal nutrition,
it may be associated with a rapid weight gain during
infancy, and may result in considerable adaptation that
develops a cluster of signs of metabolic syndrome
[55,102] with insulin resistance as the key factor. This
cluster increases the risk of experiencing comorbidities,
such as obesity, diabetes, dyslipidemia, coronary disease,
and hypertension, among others [103,104]. Indeed, the
sum of risk factors (eg, rapid weight gain, family history,
and ethnic group) all contribute to exacerbate the risk
of metabolic syndrome in children born SGA. Notably,
these children are not necessarily overweight or obese,
but have a higher “adipose” body composition that con-
tributes to the metabolic features [55]. In these cases,
detection of clinical signs of insulin resistance, such as
acanthosis nigricans, is of great importance. In addition,
t h ep e r i o d i cm o n i t o r i n go fb l o o dp r e s s u r ei sv i t a li n
these children, especially if they are overweight or obese.
The efficacy of GH treatment in children born SGA
has been confirmed by several series and by results in
final height under continuous treatment with GH
[3,44,46,51,57,105]. Nevertheless, safety in relation to
glucose metabolism in GH-treated SGA children has
been and continues to be an issue of particular impor-
tance, considering the known effect of GH on glucose
metabolism. SGA children treated with GH experience
a transient increase in serum insulin concentrations
and variable degrees of compromised glucose tolerance
[106]. These side effects, which are the result of a pre-
dictable response to the physiological actions of GH,
have been previously reported [51,107-110]. However,
no long-term effects have been observed on the
prevalence of type 2 diabetes [107]. Furthermore, the
effects on insulin resistance seem to be reversible
[56,108,111,112].
In view of the fact that a high percentage of indivi-
duals with glucose intolerance have a fasting blood glu-
cose level below 100 mg/dL, the OGTT is applicable in
children and adolescents with risk factors such as obe-
sity, family history, and hypertension. However, we do
not recommend this be indicated as a general comple-
mentary test for children born SGA, rather, it should be
individualized for children with rapid weight gain,
acanthosis nigricans, dyslipidemia (high triglycerides), or
a significant family history of metabolic syndrome [9].
Improvements in lipid profile and blood pressure asso-
ciated with the metabolic syndrome in SGA children
receiving GH treatment has also been reported [56].
Determining the concentrations of total cholesterol,
HDL and LDL cholesterol, and especially plasma trigly-
cerides are important. All of these values must be com-
pared with appropriate standards for children of
different ages.
Implementation
Use of available population-, ethnic-, or country-specific
reference data for birth weight and length, if available, is
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measurement of weight, length, and head circumference
and, particularly, accurate gestational dating are more
essential to a correct diagnosis of SGA [10]. In cases of
suspected SGA, pediatricians should obtain ultrasono-
graphic dating information, if performed during preg-
nancy. Pediatricians should also consider obtaining other
pregnancy data, immediate perinatal/postnatal data, and
early postnatal growth data, if available [10]. If possible,
identifying the cause of SGA (eg, fetal factors [genetic,
congenital anomalies], maternal factors, nutritional or
substance abuse factors, uterine/placental factors, demo-
graphic factors, and multiple gestation), is important, as
it may affect treatment. Children who do not experience
catch-up growth should receive careful long-term physi-
cal and laboratory monitoring by an endocrinologist or
pediatrician with endocrinology expertise. If necessary,
they might be placed on GH therapy early [3].
Obstetricians/gynecologists should refer pregnancies
with diagnosis of IUGR to a high-risk obstetric clinic
with special care for certain diseases (eg, platelet dys-
function, hypertension) in order to reduce the severity
of IUGR and the frequency of children born SGA.
Although high-risk clinics are usually located in big
cities, public health organizations should be aware of
the needs of these patients and develop special networks
for them. Neonatologists should be alert for the possible
consequences of acute fetal distress that may occur dur-
ing labor and/or delivery by caesarian section of an SGA
infant, in addition to all the known complications such
as respiratory distress, hypoglycemia, and hypokalemia.
A program for medical dissemination and training of
multidisciplinary team members is an important next
step. Training on the adequate management of SGA
term and preterm newborns must be provided to
pediatricians and neonatologists. Immediate, medium-,
and long-term complications must be discussed, with
an emphasis on growth problems and metabolic altera-
tions that may develop. Pediatricians are encouraged to
share their knowledge via multidisciplinary workshops.
Furthermore, it would be important to provide written
materials on the monitoring of adequate growth, the
recovery phase, and follow-up in order to detect
growth and metabolic alterations in these patients.
Policies involving the primary care physician and
pediatrician for detection and referral to a pediatric
endocrinologist for the examination and treatment of
growth and metabolic alterations in those born SGA
should be developed.
Summary
Most children born SGA recover from their weight and
height deficiency. However, 10% to 15% of children born
S G Aw i l lc o n t i n u et oh a v es hort stature. GH treatment
benefits growth potential in short-stature children born
SGA. In both sexes, gonadal function should be taken
into account, especially during puberty. Reduced fetal
growth followed by excessive postnatal catch-up in
height, and particularly in weight, should be monitored.
Excessive weight gain is most frequently associated with
metabolic risk later in life. Finally, children born SGA
should be carefully followed by a multidisciplinary group
that includes perinatologists, pediatricians, nutritionists,
and pediatric endocrinologists, in order to improve
growth, glucose homeostasis, and gonadal function.
Latin American SGA Consensus Guidelines Summary
￿ Local charts endorsed by local Pediatrics Associa-
tions are recommended. If local charts are not avail-
able, WHO growth charts may be used from birth
until age 5 years, after which the WHO Reference
2007 is recommended.
￿ Most infants born SGA recover from their weight
and height deficiency.
￿ GH treatment benefits growth potential in short-
stature children born SGA.
￿ Gonadal function in both sexes should be taken
into account, especially during puberty.
￿ Children born SGA should not be allowed to gain
weight too rapidly or excessively in an effort to cir-
cumvent the development of metabolic disturbances.
￿ Children born SGA should be followed carefully by
a multidisciplinary group.
￿ A program for medical dissemination and training
of multidisciplinary team members is needed.
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